Synlogic Inc SYBX
Trading Information
- Previous Close Price
- $1.08
- Day Range
- $1.00–1.00
- 52-Week Range
- $0.56–1.87
- Bid/Ask
- $0.96 / $1.06
- Shares Outstanding
- 12.25M
- Market Cap
- $11.70M
- Volume/Avg
- 7,044 / 64,463
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. The pipeline drug candidates includes: labafenogene marselecobac (SYNB1934); SYNB1353 Classical Homocystinuria (HCU); SYNB8802 Enteric Hyperoxaluria; and SYNB2081 Gout. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one operating segment: Discovery and development of Synthetic Biotics.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 1
- Website
- https://www.synlogictx.com
Valuation
|
Metric
|
SYBX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.97 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
SYBX
Financial Strength
|
Metric
|
SYBX
|
|---|---|
Quick Ratio | 9.02 |
Current Ratio | 9.19 |
Interest Coverage | — |
Quick Ratio
SYBX
Profitability
|
Metric
|
SYBX
|
|---|---|
Return on Assets (Normalized) | −20.57% |
Return on Equity (Normalized) | −26.84% |
Return on Invested Capital (Normalized) | −31.68% |
Return on Assets
SYBX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|HK&<w< | LOCK|&%%$k | $136B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|<Q>QKc | LOCK|Bf@! | $84B | |||
| Moderna Inc
MRNA
| LOCK|hHWJX!$ | LOCK|<D | $81B | |||
| argenx SE ADR
ARGX
| LOCK|DzcDZ> | LOCK|!% | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|#Z$lY@Q | LOCK|G$ | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|$%S^CP | LOCK|mmT^> | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|&^$^$QT# | LOCK|?x?@> | $28B | |||
| Incyte Corp
INCY
| LOCK|vxdpV^ | LOCK|P^ | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|F<&jK&N | LOCK|m& | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|<v!sr@ | LOCK|%B | $14B |
United States